GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinclair Pharma PLC (XPAR:SPH) » Definitions » Float Percentage Of Total Shares Outstanding

Sinclair Pharma (XPAR:SPH) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 19, 2024)


View and export this data going back to . Start your Free Trial

What is Sinclair Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sinclair Pharma's float shares is 0.00 Mil. Sinclair Pharma's total shares outstanding is 434.92 Mil. Sinclair Pharma's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sinclair Pharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sinclair Pharma's Institutional Ownership is 30.00%.


Sinclair Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Sinclair Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/434.92
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinclair Pharma (XPAR:SPH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinclair Pharma PLC (XPAR:SPH) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
N/A
Address
Sinclair Pharma PLC is a United Kingdom-based specialty pharmaceutical company focused on Dermatology, in particular, Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on key emerging markets through long-term multi-product, multi-country, sales & marketing and distribution deals with key strategic partners. The Company's reportable operating segments are International Operations, France, Italy, Germany, UK, and Spain.